Chronic Graft Loss & Long-Term Kidney Transplant Outcomes

Outline the long-term outcomes of renal transplantation and mechanisms of chronic graft loss.
Objectives:
- Appreciate trends in long-term renal allograft survival.
- Identify common causes of chronic graft failure.
- Recognize histologic patterns linked to chronic graft loss.
- List predictors for long-term graft survival.

Data shown for adult recipients (deceased-donor vs. living-donor).
Key numbers (2017 cohort):
- Deceased-donor 10-yr graft failure: $49.7\%$ .
- Living-donor 10-yr graft failure: $34.1\%$ .
Trend: modest improvement in 5-yr and 10-yr outcomes over successive reports.
Principle: Failure rate rises with time after transplant regardless of donor type.

Kidney Donor Profile Index (KDPI):
- Higher KDPI → lower 5-yr graft survival.
- Largest survival drop seen when KDPI >85\%.
- Difference between KDPI strata $\le 85\%$ is relatively small.
Donor mechanism of death (Brain Death vs. Donation after Cardiac Death):
- No significant difference in 5-yr graft survival between the two deceased-donor groups.

Underlying Kidney Disease (both donor sources):
- Diabetes → lowest 5-yr survival.
- Glomerulonephritis → intermediate.
- Cystic kidney disease → best survival.
Age (living donors):
- $65+$ yrs: worst 5-yr survival.
- $35$ – $49$ yrs: best 5-yr survival.
Race (living donors):
- Black recipients have lowest 5-yr survival, yet still better than deceased-donor outcomes overall.

Cohort: grafts surviving $\ge 90$ days.
Definitions:
- Early events = Acute rejection or Delayed Graft Function (DGF) before day $90$ .
- Baseline creatinine = day $90$ value.
- Index biopsy = first for-cause biopsy (proteinuria or unexplained creatinine rise).
Outcomes: death-censored graft failure.
Hazard Ratios (HR) (multivariate):
- Baseline creatinine >2 mg/dL → HR $\approx 5.1$ .
- Need for index biopsy → HR $13.8$ (highest risk).
Interpretation:
- Early events matter, but late events (necessitating biopsy) carry greater risk.
- Routine “stable” follow-up alone is insufficient; proactive surveillance needed.

OPTN–SRTR 10-yr rates:
- Deceased donor: $\approx 25\%$ .
- Living donor: >15\%.
Nearly half of all 10-yr graft loss is from DwFG.
Single-center study findings:
- DwFG cohort had lower eGFR just before death but preserved eGFR at 6 mo.
- Most DwFG biopsies showed normal histology.
- Declining eGFR ↔ higher mortality, but merely improving graft function will not eliminate DwFG.
- Leading cause of death: cardiovascular → emphasizes aggressive risk-factor modification (diabetes, HTN, CAD).

Incidence decreases over time but persists beyond 2 yrs post-transplant.
Two modern single-center studies:
- Graft loss range: $15$ – $38\%$ after BK diagnosis.
- Predictors vary:
- Study 1: rejection, high tubulitis, interstitial fibrosis on repeat biopsy.
- Study 2: high-level viremia, deceased-donor status, late acute rejection.
- High viremia → poor viral clearance.
Management dilemma: Requires ↓ immunosuppression → heightened rejection risk.
Biopsy/Histology:
- H&E: tubular epithelial nuclear enlargement, ground-glass inclusions (black arrows).
- SV40 (IHC): nuclear staining of infected tubules.
- Associated interstitial inflammation.

Multicenter study assigning causes to graft failures:
- $50\%$ of graft failures due solely to AMR.
- ~ $50\%$ of AMR-related failures involved non-adherence.
Time course (indication biopsies):
- @12 months: AMR ≈ $33\%$ of findings.
- >5 yrs: AMR becomes dominant pathology.

Histologic tissue injury
- Microvascular inflammation, TMA, or unexplained acute tubular injury.
Evidence of antibody–endothelium interaction
- Positive C4d in peritubular capillaries.
Serologic proof of donor-specific antibodies (DSA).

Representative stains:
- C4d IF and C4d IHC: linear PTC staining (red arrows) vs. blue tubular background (black arrows).
- Peritubular capillaritis: neutrophil infiltration in PTCs (black arrows).

Study: kidney–pancreas recipients with protocol biopsies up to $10$ yrs.
Goals: map timeline of IFTA, link to T-cell–mediated injury, assess immunosuppression-era effect.
Key findings:
- Inflammatory fibrosis at 1-yr biopsy:
- ↑ Serum creatinine at 3 mo.
- Persistently ↓ eGFR up to $10$ yrs.
- After >10 yrs → significantly worse graft survival.
- Proposed sequence: T-cell rejection → interstitial inflammation → inflammatory fibrosis → IFTA → dysfunction.
- Intensity of inflammatory fibrosis correlated with number of T-cell rejection episodes & immunosuppression era.
- Not pathognomonic; also seen in BK nephropathy & pyelonephritis → caution against labeling as “chronic T-cell rejection” automatically.
Histology:
- H&E: blue-purple inflammatory foci in fibrotic interstitium.
- PAS: tubulitis in atrophic tubules (blue arrow).
- Masson Trichrome: dark-blue collagen deposition = fibrosis.

Donor factors: high KDPI (>85\%), deceased-donor status.
Recipient factors: diabetic etiology, older age ( $\ge 65$ yrs), Black race, baseline creatinine >2 mg/dL.
Early events: DGF, acute rejection within $90$ days.
Late events (greater impact): need for for-cause biopsy, AMR, BK nephropathy, progressive IFTA, DwFG.
Behavioral: non-adherence → strong driver of AMR & graft loss.
Cardiovascular risk control essential to reducing DwFG.

Shift surveillance from solely early-event prevention to lifelong monitoring for late pathologies.
Emphasize patient education & adherence strategies to curb AMR.
Integrate cardiovascular risk management into transplant follow-up.
Consider protocol biopsies (or non-invasive markers) beyond the first year to detect subclinical BK, AMR, or IFTA.
Balance immunosuppression: reducing for BK vs. rejecting risk.
Need for personalized immunosuppression based on donor, recipient, and dynamic biopsy data.

Late events dominate chronic graft loss, particularly AMR, BK nephropathy, IFTA, and DwFG.
Early detection & targeted intervention against these late insults, combined with aggressive cardiovascular management and adherence support, offer the best opportunity to improve 10-year and beyond renal allograft survival.